All In Biotech

Drug Trial Radar · NCT04285827

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

May 20, 2021

Primary completion

Jul 24, 2023

Study completion Jul 24, 2023

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Feb 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD). The study involves sequential dose escalation of cohorts with between-group assessments of key safety and PK variables.

Conditions

  • Sickle Cell Disease

Interventions

  • CSL889Biological

    Administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with treatment-emergent adverse events (TEAEs) by CohortTime frame: Up to 32 days after start of CSL889 infusion
  2. Percentage of subjects with TEAEs by severity by CohortTime frame: Up to 32 days after start of CSL889 infusion
  3. Percentage of subjects with TEAEs by causality by CohortTime frame: Up to 32 days after start of CSL889 infusion

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Illinois Hospital and Health Science Systems

    Chicago, Illinois

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • University of Minnesota

    Minneapolis, Minnesota

  • Jacobi Medical Center

    The Bronx, New York

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina

  • Ohio State University

    Columbus, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Amsterdam UMC Academic Medical Center

    Amsterdam, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Liverpool University Hospital

    Liverpool, United Kingdom

  • Guys and St. Thomas

    London, United Kingdom

  • University College London Hospital

    London, United Kingdom

  • Manchester University Hospitals NHS Foundation Trust / Manchester Royal Infirmary

    Manchester, United Kingdom

  • Early Phase Unit

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.